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RESEARCH NOTE
Assessing the variability and predictability 
of adipokines (adiponectin, leptin, resistin 
and their ratios) in non-obese and obese 
women with anovulatory polycystic ovary 
syndrome
Christian Obirikorang1, William K. B. A. Owiredu1, Sandra Adu‑Afram1, Emmanuel Acheampong2, 
Evans Adu Asamoah1, Enoch Kwabena Antwi‑Boasiakoh3 and Eddie‑Williams Owiredu1* 
Abstract 
Objectives: To assess the variability and predictability of adiponectin, leptin, resistin and their ratios in non‑obese 
and obese women with anovulatory polycystic ovary syndrome (aPCOS).
Results: A total of 52 ovulatory controls (mean age = 31.63 ± 4.88 years, BMI = 25.33 ± 2.68 kg/m2); 54 non‑
obese (mean age = 32.11 ± 4.25 years, BMI = 25.72 ± 2.95 kg/m2) and 50 obese women with aPCOS (mean 
age = 33.64 ± 4.14 years, BMI = 39.19 ± 2.99 kg/m2) were recruited. The aPCOS group had lower adiponectin [13.0 
(10.49–16.59) vs 18.42 (15.72–19.92) µg/ml, p < 0.0001], adiponectin: leptin ratio (A:L) [0.60 (0.35–0.88) vs 1.19 (0.92–
1.37), p < 0.0001], and adiponectin: resistin ratio (A:R) [0.30 (0.21–0.43) vs 0.42 (0.32–0.62), p < 0.0001] but a higher lep‑
tin [20.02 (14.54–26.80) vs 16.17 (14.51–18.36) ng/ml, p < 0.0001] and leptin: resistin ratio (L:R) [0.53 (0.37–0.82) vs 0.40 
(0.27–0.48), p < 0.0001] compared to the controls. The obese aPCOS group had lower adiponectin [11.04 (5.66–13.25) 
vs 14.18 (11.04–18.02), p < 0.0001 and 18.42 (15.72–19.92) µg/ml, p < 0.0001], A:L [0.36 (0.27–0.44) vs 0.78 (0.61–1.16), 
p < 0.0001 and 1.19 (0.92–1.37), p < 0.0001], and A:R [0.24 (0.17–0.38) vs 0.40 (0.23–0.58), p < 0.0001 and 0.42 (0.32–
0.62), p < 0.0001] but a higher leptin [26.80 (14.28–32.09) vs 17.95 (14.86–21.26), p < 0.05 and 16.17 (14.51–18.36) ng/
ml, p < 0.0001] and L:R [0.63 (0.46–1.03) vs 0.41 (0.30–0.61), p < 0.0001 and 0.40 (0.27–0.48), p < 0.0001] compared to 
the non‑obese aPCOS and control group, respectively. A:L showed the best discriminatory power in predicting aPCOS 
(AUC = 0.83), followed by adiponectin alone (AUC = 0.79), L:R and leptin alone (both AUC = 0.69). Resistin alone had 
the poorest discriminatory power (AUC = 0.48).
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Introduction
Overweight and obesity are pervasive conditions which 
are considered global epidemic and threat to public 
health [1, 2]. Evidence suggest that obesity is associ-
ated with the risk of metabolic diseases such as diabetes, 
hypertension, cardiovascular disease, cancers and overall 
mortality [3–5]. There have also been reports of asso-
ciations between obesity and infertility [6, 7], particu-
larly among women due to the risk of anovulation [1, 8]. 
Anovulation is a common cause of infertility in women; 
responsible for 25–50% of female infertility [9, 10], of 
which polycystic ovary syndrome (PCOS) accounts over 
90% of cases [11].
PCOS is a multisystem, endocrinological, reproductive 
and metabolic disorder characterized by oligo- and/or 
anovulation, hyperandrogenism, and polycystic ovaries 
[12]. Obesity-related adverse alterations in adipose tis-
sue that predispose to metabolic dysregulation has been 
implicated in PCOS pathogenesis. These adverse altera-
tions include derangements in bioactive cytokines and 
adipokines such as adiponectin, leptin, and resistin [13, 
14].
Adiponectin is an adipokine secreted by adipose tis-
sues, with anti-inflammatory, anti-atherogenic, cardio-
protective, and insulin-sensitizing properties. Reduced 
adiponectin levels have been linked with obesity, T2DM, 
and PCOS [15–17]. Nonetheless, the relationship 
between altered adiponectin levels and PCOS remains 
debatable. While some studies report lower adiponec-
tin levels in PCOS independent of BMI [13, 18], others 
report similar adiponectin levels in BMI-matched PCOS 
and controls [19, 20]. Leptin is an anorexigenic peptide 
hormone secreted by white adipose tissue [21]. Likewise, 
whereas some studies report a significant positive asso-
ciation between circulating leptin levels with high body 
fat independent of PCOS [22], others report no signifi-
cant difference in circulating leptin levels between PCOS 
and age- and BMI-matched controls [23, 24] as well as 
between ovulatory and anovulatory women with PCOS 
[25]. Resistin is an adipocyte-derived polypeptide which 
have been associated with obesity, insulin resistance (IR) 
and cardiovascular risk [26, 27]. Similarly, some studies 
report comparable resistin levels between women with 
PCOS and controls [17, 27, 28] while others indicate that, 
irrespective of PCOS, there are elevated resistin levels in 
obese women compared to non-obese [29].
Thus far, reports regarding the alterations in adiponec-
tin, leptin, and resistin in non-obese and obese women 
with PCOS remain inconclusive. Additionally, despite 
numerous previous studies highlighting the expediency 
of the ratios of these adipokines as a biomarker for obe-
sity, IR, diabetes, coronary artery disease, and stroke [30–
33], there is a dearth of information on their expediency 
as predictors of PCOS. This study aimed at assessing 
the  variability and predictability of adiponectin, leptin, 
resistin and their ratios in non-obese and obese women 
with anovulatory PCOS.
Main text
Materials and methods
Study design/setting
This was a case–control study. Consecutive consent-
ing women clinically diagnosed of aPCOS visiting the 
Obstetrics and Gynaecology units of Trust Care, Ruma 
and Asbury were included in the study as cases. PCOS 
diagnosis was based on the 2003 Rotterdam criteria [12]. 
All PCOS participants were anovulatory. Fertile (eumen-
orrheic) women visiting the hospital for routine check-up 
were included as controls. Relevant clinical data of each 
participant was extracted from the hospital’s archive. 
Women with Cushing syndrome, hyperprolactinemia, 
androgen-producing tumors, non-classic adrenal hyper-
plasia, active thyroid disease, and diabetes were excluded.
Study population and Anthropometric measurements
A total of 52 ovulatory, 54 non-obese and 50 obese 
women with aPCOS were included in this study. The 
weight was measured using a calibrated analogue scale 
(Seca, Hamburg, Deutschland). Height was measured 
using a stadiometer (Seca, Hamburg, Deutschland). 
Body mass index (BMI) was calculated by: BMI = weight/
height2 (kg/m2) [34]. Obesity was defined accord-
ing to the World Health Organization (WHO) criteria 
(BMI ≥ 30  kg/m2) [35]. Waist circumference (WC) and 
hip circumference (HC) were measured with a meas-
uring tape; waist-to-height ratio (WHtR) = WC (m)/
height (m), waist-to-hip ratio (WHR) = WC (m)/HC (m), 
body adiposity index (BAI) = (100 × HC (m))/(height 
(m) × √height (m)) − 18 [36] and visceral adiposity 
index (VAI) = (WC(m))/(36.58 + (1.89 × BMI)) × (TG/
(0.81)) × ((1.52)/HDL-C) were calculated.
Blood sampling, processing and analysis
Five milliliters of venous blood was obtained from each 
participant and dispensed into gel separator tubes. The 
tubes were centrifuged at 1500×g for 10 min at 4  °C to 
obtain the serum which were stored at − 20 °C until anal-
ysis. Serum levels of adiponectin, leptin, and resistin were 
measured based on solid-phase sandwich Enzyme Linked 
Immunosorbent Assay (ELISA) technique (standardized 
with an intra- and inter-assay %CVs < 10%) (Green Stone 
Swiss Co Limited, China) according to the manufactur-
er’s instructions.
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Statistical analysis
Statistical analysis was performed using the R Lan-
guage for Statistical Computing version 3.6.0 [37]. Chi 
squared test was used to assess significance of associa-
tion between the participant characteristics and fertil-
ity status. Distribution of adipokines were presented 
with density plots. Hierarchical clustering by Spear-
man’s correlation was used to assess relationship between 
adipokines (and their ratios) and obesity indices. Inde-
pendent t-test and one-way ANOVA with Tukey test or 
Mann–Whitney U and Kruskal–Wallis with Dunn’s test 
were used to test for significance of difference between 
groups where applicable. The receiver operating char-
acteristic (ROC) curve analysis was used to evaluate the 
performance of the adipokines (and their ratios) in pre-
dicting aPCOS. A p value < 0.05 was considered statisti-
cally significant.
Results
A total of 52 ovulatory controls (mean 
age = 31.63 ± 4.88  years, BMI = 25.33 ± 2.68  kg/m2); 
104 aPCOS patients comprising 54 non-obese [mean 
age = 32.11 ± 4.25  years, BMI = 25.72 ± 2.95  kg/m2] 
and 50 obese women [mean age = 33.64 ± 4.14  years, 
BMI = 39.19 ± 2.99 kg/m2] were included in this study. A 
higher proportion of the study participants had tertiary 
education, were employed and did not consume alcohol. 
There was no statistically significant association between 
fertility status and baseline characteristics (Table 1).
The aPCOS group had a significantly lower adiponectin 
[13.0 (10.49–16.59) µg/ml vs 18.42 (15.72–19.92) µg/ml, 
p < 0.0001], adiponectin: leptin ratio (A:L) [0.60 (0.35–
0.88) vs 1.19 (0.92–1.37), p < 0.0001], and adiponectin: 
resistin ratio (A:R) [0.30 (0.21–0.43) vs 0.42 (0.32–0.62), 
p < 0.0001] but higher leptin [20.02 (14.54–26.80) ng/
ml vs 16.17 (14.51–18.36) ng/ml, p < 0.0001] and leptin: 
resistin ratio (L:R) [0.53 (0.37–0.82) vs 0.40 (0.27–0.48), 
p < 0.0001] compared to the controls (Fig. 1a, b).
The obese aPCOS group had a significantly lower adi-
ponectin [11.04 (5.66–13.25) µg/ml vs 14.18 (11.04–
18.02) µg/ml, p < 0.0001 and 18.42 (15.72–19.92) µg/ml, 
p < 0.0001], A:L [0.36 (0.27–0.44) vs 0.78 (0.61–1.16), 
p < 0.0001 and 1.19 (0.92–1.37), p < 0.0001], and A:R [0.24 
(0.17–0.38) vs 0.40 (0.23–0.58), p < 0.0001 and 0.42 (0.32–
0.62), p < 0.0001] but higher leptin [26.80 (14.28–32.09) 
ng/ml vs 17.95 (14.86–21.26) ng/ml, p < 0.05 and 16.17 
(14.51–18.36) ng/ml, p < 0.0001] and L:R [0.63 (0.46–
1.03) vs 0.41 (0.30–0.61), p < 0.0001 and 0.40 (0.27–0.48), 
p < 0.0001] compared to the non-obese aPCOS and con-
trol group, respectively (Fig. 1c, d).
Table 1 Baseline characteristics of the study population
Unless otherwise indicated, Chi squared test was used to assess significance of association between the baseline characteristics and fertility status
* Fisher exact test for test of association
‡ Significance of difference comparing Ovulatory control and PCOS group using Independent t-test
† Significance of difference comparing Ovulatory control, Non-obese PCOS, and Obese PCOS group using One-way ANOVA
Variable Ovulatory control 
(n = 52)
PCOS (n = 104) p-value Non-obese PCOS 
(n = 54)
Obese PCOS (n = 50) p-value
Age (years) 31.63 ± 4.88 32.85 ± 4.25 0.112‡ 32.11 ± 4.25 33.64 ± 4.14 0.062†
Educational level 0.312 0.219
 None/basic 5 (21.7) 18 (78.3) 12 (52.2) 6 (26.1)
 Secondary 14 (41.2) 20 (58.8) 12 (35.3) 8 (23.5)
 Tertiary 33 (33.3) 66 (66.7) 30 (30.3) 36 (36.4)
Occupation 0.197 0.093
 Unemployed 9 (47.4) 10 (52.6) 8 (42.1) 2 (10.5)
 Employed 43 (31.4) 94 (68.6) 46 (33.6) 48 (35.0)
  Informal 10 (29.4) 24 (70.6) 10 (29.4) 14 (41.2)
  Formal 33 (32.0) 70 (68.0) 36 (35.0) 34 (33.0)
Frequency of exercise 0.073 0.064
 Rarely 17 (25.4) 50 (74.6) 22 (32.8) 28 (41.8)
 1/week 22 (34.9) 41 (65.1) 26 (41.3) 15 (23.8)
 > 1/week 13 (50.0) 13 (50.0) 6 (23.1) 7 (26.9)
Alcohol consumption 0.235* 0.405*
 No 36 (30.5) 82 (69.5) 42 (35.6) 40 (33.9)
 Yes 16 (42.1) 22 (57.9) 12 (31.6) 10 (26.3)
Smoking status
 No 52 (33.3) 104 (66.7) 54 (34.6) 50 (32.1) –
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Among the aPCOS group, adiponectin showed a sig-
nificant negative correlation with BMI (rs = − 0.43, 
p < 0.0001), WHtR (rs = − 0.36, p < 0.0001), BAI 
(rs = − 0.35, p < 0.0001), and VAI (rs = − 0.19, p = 0.049). 
Leptin had a positive correlation with BMI (rs = 0.31, 
p = 0.001), WHtR (rs = 0.27, p = 0.007), and BAI 
(rs = 0.29, p = 0.003). There was no statistically signifi-
cant correlation between resistin and obesity indices. 
A:L showed a negative correlation with BMI (rs = − 0.48, 
p < 0.0001), WHtR (rs = − 0.38, p < 0.0001), and BAI 
(rs = − 0.40, p < 0.0001). A:R showed similar correla-
tions while L:R showed a positive correlation with BMI 
(rs = 0.27, p = 0.005) and BAI (rs = 0.29, p = 0.003) 
(Fig. 2a and Additional file 1: Table S1). Among the con-
trols, adiponectin showed a significantly negative cor-
relation with BAI (rs = − 0.33, p = 0.017) while resistin 
showed a positive correlation with WHR (rs = 0.31, 
p = 0.028) and WHtR (rs = 0.28, p = 0.044). There was 
no statistically significant correlation between leptin and 
obesity indices. A:L had a significant negative correlation 
with BMI (rs = − 0.36, p = 0.008) and BAI (rs = − 0.39, 
p = 0.004) while A:R showed a significant negative cor-
relation with BMI (rs = − 0.29, p = 0.038) (Fig.  2b and 
Additional file 1: Table S2).
A:L presented with the best discriminatory power in 
predicting aPCOS (AUC = 0.83) followed by adiponec-
tin alone (AUC = 0.79), and L:R and leptin alone (both 
AUC = 0.69). Resistin alone presented with the poorest 
discriminatory power (AUC = 0.48) (Fig. 2c).
Discussion
Evidence suggest that, in PCOS, high body fat coupled 
with dysfunction of adipose tissue result in over-pro-
duction of leptin, resistin and reduced expression of 
adiponectin. Levels of adiponectin have been shown to 
decrease in obesity and increase with weight loss [29]. 
It is considered a ‘beneficial’ adipokine in reproduction 
[38]. Leptin is constitutively secreted by adipocytes 
Fig. 1 Variability of adipokines and their ratios between ovulatory and aPCOS groups. a, c Density plots showing distribution of adipokines. b 
Comparison of adipokines and their ratios between case and control groups. Mann–Whitney U test was used to assess significance of difference of 
adipokines and their ratios between ovulatory and aPCOS groups. d Comparison of adipokines and their ratios. Kruskal–Wallis H test was used to 
assess significance of difference of adipokines and their ratios between ovulatory (OC), non‑obese (NOP), and obese PCOS (OP) groups. Post‑hoc 
multiple comparisons was by Dunn’s test. ns not significant, *significant at p < 0.05, ***significant at p < 0.0001
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in proportion to the adipose mass [39]. In obesity, 
the levels of leptin are even more elevated due to lep-
tin resistance [40]. Additionally, increased expression 
of the resistin gene has been observed in human pre-
adipocytes, which decreased during adipocyte differen-
tiation. Some studies report comparable adiponectin, 
leptin and resistin levels in PCOS [19, 24, 28] whiles 
others report lower adiponectin [18], higher leptin [22] 
and resistin levels [29] among women with PCOS than 
controls in relation to obesity. Thus, reports regarding 
the levels of adiponectin, leptin, and resistin in PCOS 
remain unresolved.
In this study, aPCOS patients had significantly lower 
levels of adiponectin, A:L, and A:R but higher leptin 
and L:R compared to the controls. Our finding is com-
parable to a study by Sarray et  al. [28], who reported 
significantly lower levels of adiponectin, A:L, and A:R 
among women with PCOS compared to controls in 
Bahrain. A recent study by Baldani et al. also found sig-
nificantly lower adiponectin and higher leptin among 
Fig. 2 Correlational analysis and the performance of individual adipokines and their ratios in predicting aPCOS. a Correlation among aPCOS group. 
b Correlation among ovulatory control group. Hierarchical clustering by Spearman’s correlation was used to assess relationship between adipokines 
and their ratios with obesity indices. Blue‑red coloration represents min (−) to max (+) correlation coefficient. c Receiver operating characteristic 
(ROC) curve was based on binary logistic regression and discriminant classification analysis for aPCOS and control groups. †Test direction is negative 
(smaller test results indicate presence of condition). A:L ratio adiponectin:leptin ratio, A:R ratio adiponectin:resistin ratio, L:R ratio leptin:resistin ratio
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women with PCOS compared to controls in Croatia 
[41]. Upon stratification of aPCOS group by obesity 
status, we found the obese aPCOS group to have a sig-
nificantly lower adiponectin, A:L, and A:R but higher 
leptin and L:R compared to the non-obese aPCOS and 
ovulatory group, respectively. This finding is in har-
mony with a study by Olszanecka-Glinianowicz et  al. 
[17] who found serum adiponectin and A:R to be low-
est in the obese PCOS subgroup compared to both 
the normal weight PCOS subgroup and the controls 
in Poland. In their study, serum resistin levels did not 
differ significantly between both non-obese and obese 
PCOS subgroups and the controls which is compa-
rable to our study findings. Studies by Xiu et  al. [42], 
Arikan et al. [43], and Seow et al. [44] also found simi-
lar serum resistin levels among controls, non-obese, 
obese women with PCOS. Furthermore, Sarray et  al. 
[28] found markedly reduced A:L and A:R among obese 
women with PCOS compared to non-obese women 
with PCOS and controls. They also found lower L:R 
among obese women with PCOS though not statisti-
cally significant. Together with previous findings, our 
results corroborate the deposition that high body fat 
indeed paly pivotal roles in the pathogenesis of PCOS.
Also consistent with previous reports [39, 40, 45–47], 
we found that, with the exception of resistin, all other 
adipokines including their ratios were strongly and more 
correlated with various obesity indices among women 
with aPCOS compared to the controls. Specifically, adi-
ponectin, A:L, and A:R showed a negative associations 
whereas leptin, and L:R correlated positively with the 
obesity indices. This finding is also coherent with studies 
by Sarray et al. [28] and Golbahar et al. [48].
In order to assess the predictive capabilities of the adi-
pokines and their ratios, we employed the ROC curve 
analysis with reference to aPCOS. We found A:L to have 
the best discriminatory power in predicting aPCOS 
with an AUC of 0.83, followed by adiponectin alone 
(AUC = 0.79). Adiponectin and leptin are adipose tissue-
derived hormones with contrasting relationship with 
the metabolic dysregulation [48]. Previous studies have 
highlighted A:L as a biomarker for obesity IR, and stroke 
[30–33]. Given the high AUC, our finding suggest that 
A:L could be a useful marker for aPCOS. This finding 
corroborates with a study by Golbahar et al. who found 
A:L to have a similarly high discriminatory power with 
comparable AUC of 0.86 among Bahraini women with 
PCOS [48]. Sarray et  al. found a much higher discrimi-
natory power (AUC of 0.94) for A:L in predicting PCOS 
in Bahrain [28]. The discrepancy in the predictive power 
may be attributed to differences in characteristics of the 
study population, sample size, and methods for biochem-
ical analysis.
Conclusion
This study shows significantly altered serum adi-
ponectin and leptin levels but not resistin in Ghana-
ian women with aPCOS compared to healthy subjects. 
Obese aPCOS patients have the most altered levels of 
adipokines compared to non-obese aPCOS and healthy 
subjects. Adiponectin: leptin ratio is the best predictor 
of aPCOS compared to individual adipokines.
Limitations
We did not assess androgens levels of the participants. 
Also, levels of insulin or IR was not evaluated. Further-
more, the relatively small sample size is a limitation of 
this present study. We recommend the use of larger 
sample size in future studies.
Additional file
Additional file 1. Correlation co‑efficient, lipid profile and anthropomet‑
ric characteristics of the study population.
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